logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Shusen Wang

Guangdong Provincial Clinical Research Center for Cancer
H指数:39
被引数:6,516

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS)

新辅助同时或序贯含蒽环类化疗联合HER2靶向药物用于HER2阳性乳腺癌的随机II期研究（METIS）

Signal Transduction and Targeted Therapy
IF52.7
2026-11-020
OAAI
Qiufan Zheng; Shusen Wang; Zhiyong Wu; Muyi Zhong; Fei Xu; Shihui Ma; Yuanqi Zhang; Lehong Zhang; Yanxia Shi; Ying Wang; Heng Huang; Xiaopeng Ma; Xiangdong Xu; Haiyan Li; Jibin Li; Xiwen Bi; Jiajia Huang; Kuikui Jiang; Xin An; Ruoxi Hong; Meiting Chen; Cong Xue; Yongyi Zhong; Zhongyu Yuan; Wen Xia
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial

氟维司群与卡培他滨作为激素受体阳性HER2-negative转移性乳腺癌一线化疗后的维持治疗 (FAMILY): 一项多中心、开放标签、随机、3期临床试验

Signal Transduction and Targeted Therapy
IF52.7
2026-05-220
OAAI
Wenjing Wu; Yaping Yang; Haizhu Chen; Yongkui Lu; Yinduo Zeng; Jianli Zhao; Caiwen Du; Ying Lin; Peijian Peng; Mei Huang; Ying Zhang; Quchang Ouyang; Linxiaoxiao Ding; Ziliang Cheng; Yuanyu Wen; Zhiyong Wu; Jinhui Ye; Li Ling; Kun Wang; Ying Lu; Guorong Zou; Jincai Zhong; Hong Wang; Daren Lin; De Zeng; Chengcai Yao; Qianjun Chen; Liqun Zou; Shusen Wang; Yunfang Yu; Zhongyu Yuan; Ying Wang; Herui Yao
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)

HDAC抑制剂tucidinostat和节拍卡培他滨联合内分泌治疗CDK4/6抑制剂治疗后HR阳性HER2-negative晚期乳腺癌患者: 一项多中心2期研究的临床发现和探索性循环肿瘤细胞和ctDNA生物标志物分析 (SYSUCC-020试验)

Signal Transduction and Targeted Therapy
IF52.7
2026-04-150
OAAI
Huai-liang Wu; Wen Xia; Zhengyang Xu; Hanxing Zhou; Limin Chen; Yongkui Lu; Xinlan Liu; Danmei Pang; Yan Liu; Qianyi Lu; Fei Xu; Xin An; Jiajia Huang; Kuikui Jiang; Jingmin Zhang; Yili Cai; Ruoxi Hong; Qiufan Zheng; Shusen Wang
Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study

T-DXd在HER2+和低/零转移性乳腺癌脑转移（BCBM）中的有效性与安全性：一项回顾性多中心真实世界研究

Cancer Science
IF4.3
2025-09-110
OAAI
Qingru Zhou; Yuanyuan Li; Ni He; Guorong Zou; Mengqian Ni; Lulu Zhang; Shu Dun; Zhanhong Chen; Kejun Liu; Yabing Cao; Jiajia Huang; Fei Xu; Zhongyu Yuan; Shusen Wang; Yanxia Shi; Yonggao Mou; Anli Yang; Lixia Li; Xin An
HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy

HER2阳性伴有浸润性微乳头状癌成分的乳腺癌表现出免疫抑制性微环境和对新辅助治疗的抵抗

Frontiers in Immunology
IF5.9
2025-08-020
OA
Lulu Zhang†; Lijia Zhou†; Anli Yang†; Shaoquan Zheng; Keming Chen; Yutian Zou; Qingru Zhou; Daining Wang; Fei Xu; Jiajia Huang; Zhongyu Yuan; Shusen Wang; Yanxia Shi; Peng Sun; Xin An
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

TROPION-Breast05：一项关于Dato-DXd联合或不联合durvalumab与化疗联合pembrolizumab治疗PD-L1高表达局部复发不可手术或转移性三阴性乳腺癌的随机III期研究

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2025-04-170
OA
Peter Schmid; Mafalda Oliveira; Joyce O’Shaughnessy; Massimo Cristofanilli; Stephanie L. Graff; Seock-Ah Im; Sherene Loi; Shigehira Saji; Shusen Wang; David W. Cescon; Tina Hovey; Agata Nawrot; Karson Tse; Petra Vukovic; Giuseppe Curigliano
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

Sacituzumab tirumotecan在既往治疗过的转移性三阴性乳腺癌中的疗效：一项随机III期临床试验

NATURE MEDICINE
IF50
2025-04-111
PRE
Yin, Yongmei; Fan, Ying; Ouyang, Quchang; Song, Lihua; Wang, Xiaojia; Li, Wei; Li, Man; Yan, Xi; Wang, Shusen; Sun, Tao; Teng, Yuee; Tang, Xianjun; Tong, Zhongsheng; Sun, Zhengkui; Ge, Junyou; Jin, Xiaoping; Diao, Yina; Liu, Gesha; Xu, Binghe
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer

ACE-Breast-02：一项比较ARX788与拉帕替尼联合卡培他滨治疗HER2阳性晚期乳腺癌的随机III期试验

SIGNAL TRANSDUCTION AND TARGETED THERAPY
IF52.7
2025-02-173
OA
Hu, Xichun; Zhang, Qingyuan; Wang, Leiping; Zhang, Jian; Ouyang, Quchang; Wang, Xiaojia; Li, Wei; Xie, Weimin; Tong, Zhongsheng; Wang, Shusen; Xu, Faliang; Sun, Tao; Liu, Wei; Chen, Zhendong; Wu, Jinsheng; Wang, Ying; Wang, Haixia; Yan, Min; Wang, Xinshuai; Wang, Jingfen; Cao, Feilin; Du, Yingying; Zhang, Yongqiang; Chen, Lilin; Lu, Ping; Sun, Sanyuan; Zhang, Ruiwen; Zang, Aimin; Nie, Xiuqing; Lei, Yuan
Lerociclib plus fulvestrant in patients with HR+/HER2-locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Lerociclib联合fulvestrant用于接受过先前内分泌治疗并进展的HR+/HER2-局部晚期或转移性乳腺癌患者的治疗：LEONARDA-1一项III期随机试验

NATURE COMMUNICATIONS
IF15.7
2025-01-160
OA
Xu, Binghe; Zhang, Qingyuan; Luo, Yang; Tong, Zhongsheng; Sun, Tao; Shan, Changping; Liu, Xinlan; Yao, Yumin; Zhao, Bing; Wang, Shusen; Zeng, Xiaohua; Hu, Changlu; Yan, Xi; Wang, Xiaojia; Jia, Hongyan; Chen, Zhendong; Qiu, Fuming; Wu, Xinhong; Zhang, Deyong; Li, Tong

研究方向

暂未获取到该数据
R
Ruoxi Hong
H 指数:19论文数:110被引数:1,608
徐飞 封面图
徐飞
H 指数:33论文数:197被引数:4,145
袁
袁中玉
H 指数:28论文数:181被引数:3,002
Q
Qianyi Lu
H 指数:12论文数:71被引数:461
K
Kuikui Jiang
H 指数:11论文数:63被引数:593
史
史艳侠
H 指数:24论文数:129被引数:2,726
W
Wen Xia
H 指数:26论文数:130被引数:1,886
Z
Zhongsheng Tong
H 指数:31论文数:220被引数:4,968
徐兵河 封面图
徐兵河
H 指数:63论文数:785被引数:2.8万
Q
Qiufan Zheng
H 指数:14论文数:85被引数:854